Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer (May 2020)

Thursday, May 28, 2020
Webinar -- 3:00 PM CEST
http://www.clinicaloptions.com/ESMOBreast2020Join1

Agenda

Program Overview (5 min)

Novel Therapies for Relapsed/Refractory HER2 MBC (30 min)

  • New anti-HER2-directed antibody–drug conjugates
  • Future directions for antibody-based therapies for HER2-positive breast cancer

Case Discussions: Management of Relapsed/Refractory HER2 MBC Today (20 min)

  • Selecting treatment for patients HER2-positive MBC following relapse on traditional HER2 targeted agents
  • Selecting treatment for patients with previously treated HER2-positive MBC and CNS metastases

Question and Answer Session (5 min)

Faculty

Program Director
Adam Brufsky, MD

Professor of Medicine
Hematology/Oncology
University of Pittsburgh School of Medicine
Associate Chief, Hematology-Oncology
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania USA

Faculty
Thomas Bachelot, MD, PhD

Chair, Unicancer Breast Group - UCBG
Breast Cancer Unit
Medical Oncology
Centre Leon Bérard
Lyon, France

Faculty
Cristina Saura, MD, PhD

Medicine and Surgery/Medical Oncology
Universidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)
Head, Breast Cancer Program
Medical Oncology
Vall d’Hebrón University Hospital
Barcelona, Spain

Goal Statement
The goal of this activity is to improve the knowledge, competence and performance of learners to integrate new and emerging therapies into treatment for HER2-positive breast cancer treatment.

Target Audience 
This program is intended for global medical oncologists and other healthcare providers who care for patients with breast cancer.

Learning Objectives 

  • Integrate recent practice-changing advances in the treatment of HER2-positive MBC
  • Identify new and emerging therapies for third line and beyond for HER2-positive MBC
  • Assess clinical trial results for novel HER2-directed and targeted therapies in this setting

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.